Bill
HB 1186
North Carolina will test field drug-detection devices that use digital signatures and an updatable library to improve accuracy, safety, and evidence handling in investigations.
Title: Equipping Law Enf. for Better Drug Detection
Sponsor: Rep. Allen Chesser (with co-sponsors Reece Pyrtle, Heather Rhyne, Phil Rubin)
Goal and purpose
- Establish a pilot program through the North Carolina Collaboratory to equip participating law enforcement agencies with advanced, non-color-based drug-detection technology.
- Objective: improve controlled-substance investigations, increase accuracy, enhance officer safety, and reduce the risk of false arrests due to unreliable presumptive field tests.
Key provisions and requirements
1) Establishment of a pilot program
- The NC Collaboratory must design and run a pilot that provides selected law enforcement agencies with new drug-detection devices.
- The program will measure impacts on:
- Case clearance and drug-enforcement outcomes
- Officer safety
- Accuracy of controlled-substance testing
- Identification of new or novel substances
- Drug-organization investigations
- Overall cost-effectiveness
2) Technology standards for participating devices
- Devices must:
- Be portable/field-deployable
- Not rely primarily on color changes or color-based tests (e.g., reagent strips, colorimetric tests)
- Generate and retain a digital analytical signature for auditability
- Compare signatures to an updatable electronic reference library to produce an objective result OR indicate “no match/unknown”
- Include an update-capable reference library for emerging substances
- Record results, the analytical signature, date/time, and device identifier
- Allow evaluator access to test records and underlying signatures for audits
3) Research and evaluation design
- The Collaboratory must use both quantitative and qualitative methods to answer questions such as:
- How device use affects arrests, case timelines, dispositions
- Changes in lab-confirmed negative outcomes
- Impacts on workload, safety, evidentiary workflows
- Variations by race/ethnicity, geography, offense type
- Additional relevant questions determined by the Collaboratory
- Data gathering includes collaboration with state agencies (courts, crime lab) and data sharing with appropriate privacy protections.
4) Data access and cooperation
- State agencies holding relevant data must provide access where permitted by law.
- Participating law enforcement agencies must cooperate, including making personnel and records available.
- Protections exist to avoid disclosure of ongoing investigations or confidential information.
5) Participating agencies and representativeness
- The Collaboratory will select agencies representing rural and urban areas and drug-trafficking corridors (I-85 and I-95).
6) Reporting and oversight
- Interim reports every three months starting three months after the act’s effective date.
- A final report within two years of funding, detailing findings.
7) Funding and duration
- Appropriation: $1,750,000 in nonrecurring General Fund dollars for FY 2026-2027.
- Funds cover equipment, development, and staffing costs.
- Unspent funds do not revert at year-end and remain available until the pilot expires.
8) Definitions and legal scope
- “Drug-detection device” = device detecting controlled substances, not impairment or intoxication.
- The bill does not alter existing standards of proof for arrests/convictions or change admissibility of current drug tests.
Effective date and expiration
- Section 7 (appropriation) becomes effective July 1, 2026.
- The rest of the act becomes law when enacted.
- The pilot expires upon final reported findings or December 1, 2028, whichever comes first.
Impact overview
- Aims to modernize field drug testing, reduce false positives, improve officer safety, and provide data-driven evidence on the effectiveness and efficiency of newer detection technologies in real-world law enforcement settings.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
